Corneal cross-linking (CXL) is effective in reducing the severity of infectious keratitis caused by Fusarium solani.
Corneal cross-linking (CXL) is effective in reducing the severity of infectious keratitis caused by Fusarium solani, according to a study in the Journal of Cornea and External Disease.
Dr Gustavo Galperin, Laboratorio de Investigaciones Oculares, Buenos Aires, Argentina, led an investigation on 24 rabbits innoculated with Fusarium solani in the stromata of the right cornea.
All rabbits were divided into two groups. Group 1 was treated with CXL 72 hours after inoculation and group 2, acting as control, received no treatment. In both groups all eyes were assessed preoperatively on days 0 and 3, and postoperatively on day 7. Eyes were enucleated and the corneal buttons were microbiologically and histologically examined.
Clinical scores were statistically significant between the two groups after CXL, with group 1 demonstrating a significantly lower clinical score. Group 1 had 22.45 ± 5.09 CFU/g compared with 42.5 ± 3.12 CFU/g in group 2.
Similar amounts of Fusarium hyphae and inflammatory cells were found in 3 corneal buttons from group 2. In 2 of the 3 buttons obtained from group 1 there were fewer Fusarium hyphae, inflammatory cells, and nonspecific stromal changes than in group 2.
The study results suggest that CXL could be helpful as a coadjuvant for the treatment of resistant fungal infections.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.